Active Ingredient History
Pegaptanib is a selective vascular endothelial growth factor (VEGF) antagonist indicated for the treatment of neovascular (wet) age-related macular degeneration. Pegaptanib is an aptamer, a pegylated modified single-stranded oligonucleotide, which adopts a threedimensional conformation that enables it to bind to extracellular VEGF. Pegaptanib specifically binds to the 165 isoform of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes responsible for the vision loss associated with neovascular age-related macular degeneration. Pegaptanib is administered in a 0.3 mg dose once every six weeks by intravitreal injection. An intravitreal injection is one that is administered directly into the eye, more specifically, into the vitreous humour, or the jelly-like fluid within the eye. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Macular Degeneration (approved 2004)
Choroidal Neovascularization (Phase 3)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetes Mellitus, Type 2 (Phase 2)
Diabetic Retinopathy (Phase 4)
Drugs, Investigational (Phase 3)
Macula Lutea (Phase 4)
Macular Degeneration (Phase 4)
Macular Edema (Phase 4)
Neovascularization, Pathologic (Phase 4)
Retinal Diseases (Phase 3)
Retinal Vein Occlusion (Phase 4)
von Hippel-Lindau Disease (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue